2019
Hidradenitis suppurativa Epidemiology, clinical presentation, and pathogenesis
Goldburg S, Strober B, Payette M. Hidradenitis suppurativa Epidemiology, clinical presentation, and pathogenesis. Journal Of The American Academy Of Dermatology 2019, 82: 1045-1058. PMID: 31604104, DOI: 10.1016/j.jaad.2019.08.090.Peer-Reviewed Original ResearchConceptsClinical presentationPilosebaceous-apocrine unitPathogenesis of HSRole of cytokinesMedical education seriesQuality of lifeSinus tractPerianal areaInflammatory cytokinesInflammatory disordersHS pathogenesisFollicular hyperkeratosisInguinal areaLesion formationSubmammary foldPathogenesisCytokinesEducation seriesEpidemiologyPresentationRecent understandingPathogenic microorganismsSuppurativaAbscessPainHidradenitis suppurativa Current and emerging treatments
Goldburg S, Strober B, Payette M. Hidradenitis suppurativa Current and emerging treatments. Journal Of The American Academy Of Dermatology 2019, 82: 1061-1082. PMID: 31604100, DOI: 10.1016/j.jaad.2019.08.089.Peer-Reviewed Original ResearchConceptsHidradenitis suppurativaPathogenesis of HSNumerous clinical trialsPotential therapeutic roleMedical education seriesAnticytokine therapyTreatment optionsHS pathogenesisClinical trialsTherapeutic roleNovel therapiesNew therapiesTherapyPathogenesisEducation seriesRecent studiesTreatmentSuppurativaSurgeryCytokinesEtiologyTrials
2018
Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials. British Journal Of Dermatology 2018, 180: 67-75. PMID: 30188571, PMCID: PMC7379291, DOI: 10.1111/bjd.17149.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAgedAged, 80 and overChronic DiseaseDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexYoung AdultConceptsSevere chronic plaque psoriasisChronic plaque psoriasisEfficacy end pointBenefit-risk profileSevere psoriasisPlaque psoriasisWeek 16Dermatology Life Quality Index scoresLong-term extension studyOral Janus kinase inhibitorGlobal assessmentLife Quality Index scoresEnd pointDepression Scale depression scorePhysician global assessmentImproved patients' qualitySystemic psoriasis therapiesJanus kinase inhibitorQuality Index scoresTofacitinib 5Tofacitinib exposurePsoriasis AreaSystemic treatmentTofacitinib treatmentPatients' quality
2017
Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal Of The American Academy Of Dermatology 2017, 78: 70-80. PMID: 29102053, DOI: 10.1016/j.jaad.2017.08.051.Peer-Reviewed Original ResearchConceptsImpact of treatmentPsoriasis Longitudinal AssessmentConventional therapyAdverse eventsDepressive symptomsIncidence rateLongitudinal assessmentConventional systemic therapiesSevere psoriasisBiologic therapySystemic therapyLower incidenceStudy populationPatientsTherapySymptomsPsoriasisRegistryBiologicsPhototherapyDepressionIncidenceMultivariate modelingRiskTreatment
2011
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials
Lebwohl M, Leonardi C, Griffiths C, Prinz J, Szapary P, Yeilding N, Guzzo C, Li S, Hsu M, Strober B. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. Journal Of The American Academy Of Dermatology 2011, 66: 731-741. PMID: 21930328, DOI: 10.1016/j.jaad.2011.06.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug-Related Side Effects and Adverse ReactionsEtanerceptEvaluation Studies as TopicFemaleFollow-Up StudiesHumansImmunoglobulin GMaleMiddle AgedPsoriasisReceptors, Tumor Necrosis FactorRisk AssessmentSafety ManagementSeverity of Illness IndexTime FactorsTreatment OutcomeUstekinumabConceptsRate of AEsUstekinumab-treated patientsAdverse eventsSerious AEsSevere psoriasisSafety profileLong-term safety experiencePrevious short-term reportsCumulative safety dataGeneral safety parametersPlacebo-controlled periodSerious adverse eventsYears of treatmentShort-term reportsCases of demyelinationUstekinumab exposureIL-23Clinical trialsOverall infectionSafety dataACCEPT trialPatientsSimilar findingsSafety experienceTrials
2010
Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis
Langley R, Strober B, Gu Y, Rozzo S, Okun M. Benefit‐risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal Of Dermatology 2010, 162: 1349-1358. PMID: 20394634, DOI: 10.1111/j.1365-2133.2010.09707.x.Peer-Reviewed Original ResearchConceptsTumor necrosis factorAdverse eventsTumor necrosis factor antagonistsMalignant adverse eventsOpen-label dataPlacebo-controlled periodAnti-TNF therapyNecrosis factor antagonistsTreatment of psoriasisTreatment effect dataBenefit-risk balanceBenefit-risk assessmentTNF antagonistsNNT valuesEfficacy measuresClinical trialsNecrosis factorSerious toxicitySafety dataFactor antagonistsLower riskEtanerceptPsoriasisAdalimumabInfliximab
2009
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
Strober B, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, Siu K, Lustgarten J, Ross E, Shapiro J. Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study. JAMA Dermatology 2009, 145: 1262-1266. PMID: 19917955, DOI: 10.1001/archdermatol.2009.264.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultAgedAlefaceptAlopecia AreataDermatologic AgentsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansInjections, IntramuscularMaleMiddle AgedNew York CityProbabilityRecombinant Fusion ProteinsRisk AssessmentSeverity of Illness IndexStatistics, NonparametricTreatment OutcomeYoung AdultConceptsSevere alopecia areataAlopecia areataPlacebo-controlled clinical trialEfficacy of alefaceptPlacebo-receiving groupSevere plaque psoriasisMain outcome measuresPlaque psoriasisPrevious therapyAlopecia ToolClinical trialsAlefaceptOutcome measuresUS FoodDrug AdministrationConsecutive weeksBiologic inhibitorsScalp hairAreataTreatmentWeeksSignificant improvementMulticenterPlaceboPsoriasis
2008
Efalizumab-Associated Guillain-Barré Syndrome
Victor F, Menon K, Latkowski J, Fernandez-Obregon A, Strober B. Efalizumab-Associated Guillain-Barré Syndrome. JAMA Dermatology 2008, 144: 1396-1397. PMID: 18936412, DOI: 10.1001/archderm.144.10.1396.Peer-Reviewed Original Research